Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH

• CAT Number: I042493
• CAS Number: 2750350-39-9
• Molecular Formula: C34H43N3O7
• Molecular Weight: 605.72
• Purity: ≥95%
• Synonyms: 2-[3-[4-[3-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methylcarbamoyl]-5-[ethyl(oxan-4-yl)amino]-4-methylphenyl]phenoxy]propoxy]acetic acid
• InChI: InChI=1S/C34H43N3O7/c1-5-37(27-11-15-42-16-12-27)31-19-26(25-7-9-28(10-8-25)44-14-6-13-43-21-32(38)39)18-29(24(31)4)33(40)35-20-30-22(2)17-23(3)36-34(30)41/h7-10,17-19,27H,5-6,11-16,20-21H2,1-4H3,(H,35,40)(H,36,41)(H,38,39)
• InChIKey: CLDOGTJZRUKKBD-UHFFFAOYSA-N
• SMILES: CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)OCCCOCC(=O)O

Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH (Cat No.: I042493) is a derivative of tazemetostat, an inhibitor of EZH2 (enhancer of zeste homolog 2), a histone methyltransferase involved in gene silencing through H3K27 trimethylation. This modified form incorporates a carboxylic acid functional group via a C3 linker, potentially enhancing solubility or enabling conjugation in drug design. Like tazemetostat, it may modulate epigenetic regulation in cancers with EZH2 overexpression or mutation. This compound is useful in exploring structure–activity relationships and developing targeted epigenetic therapies.

Reference

[1]. Tu Y, et al. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma. J Med Chem. 2021 Jul 22;64(14):10167-10184.
[Content Brief]